248 related articles for article (PubMed ID: 32388451)
1. COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach.
Borriello G; Ianniello A
Mult Scler Relat Disord; 2020 Jun; 41():102165. PubMed ID: 32388451
[TBL] [Abstract][Full Text] [Related]
2. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
Maarouf A; Rico A; Boutiere C; Perriguey M; Demortiere S; Pelletier J; Audoin B;
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32587103
[TBL] [Abstract][Full Text] [Related]
3. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
4. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Louapre C; Maillart E; Roux T; Pourcher V; Bussone G; Lubetzki C; Papeix C
Rev Neurol (Paris); 2020 Jun; 176(6):523-525. PubMed ID: 32362357
[No Abstract] [Full Text] [Related]
5. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
[No Abstract] [Full Text] [Related]
6. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
[TBL] [Abstract][Full Text] [Related]
7. Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices.
Mateen FJ; Rezaei S; Alakel N; Gazdag B; Kumar AR; Vogel A
J Neurol; 2020 Dec; 267(12):3467-3475. PubMed ID: 32638107
[TBL] [Abstract][Full Text] [Related]
8. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
[TBL] [Abstract][Full Text] [Related]
9. Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic.
Bringeland GH; Blaser N; Myhr KM; Vedeler CA; Gavasso S
J Neurol Sci; 2021 Oct; 429():117622. PubMed ID: 34474301
[TBL] [Abstract][Full Text] [Related]
10. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis.
Chisari CG; Grimaldi LM; Salemi G; Ragonese P; Iaffaldano P; Bonavita S; Sparaco M; Rovaris M; D'Arma A; Lugaresi A; Ferrò MT; Grossi P; Di Sapio A; Cocco E; Granella F; Curti E; Lepore V; Trojano M; Patti F;
J Neurol Neurosurg Psychiatry; 2020 Dec; 91(12):1297-1303. PubMed ID: 33055141
[TBL] [Abstract][Full Text] [Related]
11. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
Valencia-Sanchez C; Wingerchuk DM
Mult Scler Relat Disord; 2020 Jul; 42():102182. PubMed ID: 32416330
[TBL] [Abstract][Full Text] [Related]
12. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
[TBL] [Abstract][Full Text] [Related]
13. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Guevara C; Villa E; Rosas CS; Diaz V; Naves R
Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
[No Abstract] [Full Text] [Related]
14. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
De Angelis M; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
Mult Scler Relat Disord; 2020 Oct; 45():102452. PubMed ID: 32823148
[TBL] [Abstract][Full Text] [Related]
15. Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic.
Rath L; Bui MV; Ellis J; Carey J; Baker J; Taylor L; Fernando H; Taylor N; Savage P; Richards J; Zhong M; Kalincik T; Skibina O; Wesselingh R; Nguyen AL; Monif M; Butzkueven H; van der Walt A
Mult Scler Relat Disord; 2021 Jan; 47():102642. PubMed ID: 33321356
[TBL] [Abstract][Full Text] [Related]
16. Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
Chiarini M; Paghera S; Moratto D; Rossi N; Giacomelli M; Badolato R; Capra R; Imberti L
J Neuroimmunol; 2020 Aug; 345():577282. PubMed ID: 32505908
[TBL] [Abstract][Full Text] [Related]
17. Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis.
Devogelaere J; D'hooghe MB; Vanderhauwaert F; D'haeseleer M
Neurol Sci; 2020 Aug; 41(8):1981-1983. PubMed ID: 32564270
[TBL] [Abstract][Full Text] [Related]
18. Extended interval dosing of natalizumab: More evidence in support.
Toljan K; Conway DS
Neurotherapeutics; 2024 Apr; 21(3):e00351. PubMed ID: 38531713
[No Abstract] [Full Text] [Related]
19. Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study.
Riancho J; Setien S; Sánchez de la Torre JR; Torres-Barquin M; Misiego M; Pérez JL; Castillo-Triviño T; Menéndez-García C; Delgado-Alvarado M
Front Immunol; 2021; 12():614715. PubMed ID: 33841397
[TBL] [Abstract][Full Text] [Related]
20. Can Levamisole be used in the treatment of COVID-19 patients presenting with diarrhea?
Uyaroğlu OA; Güven GS; Güllü İ
J Infect Dev Ctries; 2020 Aug; 14(8):844-846. PubMed ID: 32903227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]